High-dose enzyme replacement therapy in murine Hurler syndrome

Molecular Genetics and Metabolism

Volumn 111, Issue 2, 2014, Pages 116-122

  Ou, Li ^a,b   Herzog, Tyler ^b   Koniar, Brenda L ^a,b   Gunther, Roland ^a,b   Whitley, Chester B ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Blood brain barrier; Enzyme replacement therapy; High dose; Hurler syndrome; Mucopolysaccharidosis I

Indexed keywords

GANGLIOSIDE GM3; LARONIDASE; LEVO IDURONIDASE; WATER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOG; DRUG HALF LIFE; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPLACEMENT; HURLER SYNDROME; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; T-MAZE TEST; TISSUE HOMOGENATE; WILD TYPE;

MURINAE; MUS;

BBB; BLOOD-BRAIN-BARRIER; ENZYME REPLACEMENT THERAPY; ERT; HIGH DOSE; HURLER SYNDROME; IDUA; MPS; MUCOPOLYSACCHARIDOSIS; MUCOPOLYSACCHARIDOSIS I; Α-L-IDURONIDASE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; COGNITION; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; ENZYME REPLACEMENT THERAPY; GLYCOSAMINOGLYCANS; HUMANS; IDURONIDASE; MAZE LEARNING; MICE; MICE, TRANSGENIC; MUCOPOLYSACCHARIDOSIS I; RECOMBINANT PROTEINS;

EID: 84893687476     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2013.09.008     Document Type: Article

References (32)

1. Giugliani R., Federhen A., Rojas M.V., Vieira T., Artigalás O., Pinto L.L., Azevedo A.C., Acosta A., Bonfim C., Lourenço C.M., Kim C.A., Horovitz D., Bonfim D., Norato D., Marinho D., Palhares D., Santos E.S., Ribeiro E., Valadares E., Guarany F., de Lucca G.R., Pimentel H., de Souza I.N., Correa J., Fraga J.C., Goes J.E., Cabral J.M., Simionato J., Llerena J., Jardim L., Giuliani L., da Silva L.C., Santos M.L., Moreira M.A., Kerstenetzky M., Ribeiro M., Ruas N., Barrios P., Aranda P., Honjo R., Boy R., Costa R., Souza C., Alcantara F.F., Avilla S.G., Fagondes S., Martins A.M. Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet. Mol. Biol. 2010, 33:589-604.
2. Urayama A., Grubb J.H., Sly W.S., Banks W.A. Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:12658-12663.
3. Zhao K.W., Faull K.F., Kakkis E.D., Neufeld E.F. Carbohydrate structures of recombinant human alpha-l-iduronidase secreted by Chinese hamster ovary cells. J. Biol. Chem. 1997, 272:22758-22765.
4. Begley D.J., Pontikis C.C., Scarpa M. Lysosomal storage diseases and the blood-brain barrier. Curr. Pharm. Des. 2008, 14:1566-1580.
5. Enns G.M., Huhn S.L. Central nervous system therapy for lysosomal storage disorders. Neurosurg. Focus. 2008, 24:3-4.
6. Dunder U., Kaartinen V., Valtonen P., Väänänen E., Kosma V.M., Heisterkamp N., Groffen J., Mononen I. Enzyme replacement therapy in a mouse model of aspartylglycosaminuria. FASEB J. 2000, 14:361-367.
7. Lee W.C., Courtenay A., Troendle F.J., Stallings-Mann M.L., Dickey C.A., DeLucia M.W., Dickson D.W., Eckman C.B. Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy. FASEB J. 2005, 19:1549-1551.
8. Vogler C., Levy B., Grubb J.H., Galvin N., Tan Y., Kakkis E., Pavloff N., Sly W.S. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:14777-14782.
9. Roces D.P., Lüllmann-Rauch R., Peng J., Balducci C., Andersson C., Tollersrud O., Fogh J., Orlacchio A., Beccari T., Saftig P., von Figura K. Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: a preclinical animal study. Hum. Mol. Genet. 2004, 13:1979-1988.
10. Blanz J., Stroobants S., Lüllmann-Rauch R., Morelle W., Lüdemann M., D'Hooge R., Reuterwall H., Michalski J.C., Fogh J., Andersson C., Saftig P. Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice. Hum. Mol. Genet. 2008, 17:3437-3445.
11. Matzner U., Herbs E., Hedayati K.K., Lüllmann-Rauch R., Wessig C., Schröder S., Eistrup C., Möller C., Fogh J., Gieselmann V. Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum. Mol. Genet. 2005, 14:1139-1152.
12. Matzner U., Lüllmann-Rauch R., Stroobants S., Andersson C., Weigelt C., Eistrup C., Fogh J., D'Hooge R., Gieselmann V. Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy. Mol. Ther. 2009, 17:600-606.
13. Polito V.A., Abbondante S., Polishchuk R.S., Nusco E., Salvia R., Cosma M.P. Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy. Hum. Mol. Genet. 2010, 19:4871-4885.
14. Crawley A.C., King B., Berg T., Meikle P.J., Hopwood J.J. Enzyme replacement therapy in alpha-mannosidosis guinea-pigs. Mol. Genet. Metab. 2006, 89:48-57.
15. Rozaklis T., Beard H., Hassiotis S., Garcia A.R., Tonini M., Luck A., Pan J., Lamsa J.C., Hopwood J.J., Hemsley K.M. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA. Exp. Neurol. 2011, 230:123-130.
16. Garcia-Rivera M.F., Colvin-Wanshura L.E., Nelson M.S., Nan Z., Khan S.A., Rogers T.B., Maitra I., Low W.C., Gupta P. Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy. Brain Res. Bull. 2007, 74:429-438.
17. Del Arco A., Segovia G., Garrido P., de Blas M., Mora F. Stress, prefrontal cortex and environmental enrichment: studies on dopamine and acetylcholine release and working memory performance in rats. Behav. Brain Res. 2007, 176:267-273.
18. Wolf D.A., Lenander A.W., Nan Z., Belur L.R., Whitley C.B., Gupta P., Low W.C., McIvor R.S. Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I. Neurobiol. Dis. 2011, 43:123-133.
19. Di Domenico C., Villani G.R., Di Napoli D., Reyero E.G., Lombardo A., Naldini L., Di Natale P. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector. Hum. Gene Ther. 2005, 16:81-90.
20. Shull R.M., Kakkis E.D., McEntee M.F., Kania S.A., Jonas A.J., Neufeld E.F. Enzyme replacement in a canine model of Hurler syndrome. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:12937-12941.
21. Dickson P., Peinovich M., McEntee M., Lester T., Le S., Krieger A., Manuel H., Jabagat C., Passage M., Kakkis E.D. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J. Clin. Invest. 2008, 118:2868-2876.
22. Guffon N., Souillet G., Maire I., Straczek J., Guibaud P. Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J. Pediatr. 1998, 133:119-125.
23. Peters C., Balthazor M., Shapiro E.G., King R.J., Kollman C., Hegland J.D., Henslee-Downey J., Trigg M.E., Cowan M.J., Sanders J., Bunin N., Weinstein H., Lenarsky C., Falk P., Harris R., Bowen T., Williams T.E., Grayson G.H., Warkentin P., Sender L., Cool V.A., Crittenden M., Packman S., Kaplan P., Lockman L.A., Anderson J., Krivit W., Dusenbery K., Wagner J. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996, 87:4894-4902.
24. Peters C., Shapiro E.G., Anderson J., Henslee-Downey P.J., Klemperer M.R., Cowan M.J., Saunders E.F., de Alarcon P.A., Twist C., Nachman J.B., Hale G.A., Harris R.E., Rozans M.K., Kurtzberg J., Grayson G.H., Williams T.E., Lenarsky C., Wagner J.E., Krivit W. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood 1998, 91:2601-2608.
25. Banks W.A. Are the extracellular [correction of extracelluar] pathways a conduit for the delivery of therapeutics to the brain?. Curr. Pharm. Des. 2004, 10:1365-1370.
26. Baldo G., Mayer F.Q., Martinelli B.Z., Carvalho T.G., Meyer F.S., Oliveira P.G., Meurer L., Tavares A., Matte U., Giugliani R. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice. Mol. Genet. Metab. 2013, 109:33-40.
27. Dierenfeld A.D., McEntee M.F., Vogler C.A., Vite C.H., Chen A.H., Passage M., Le S., Shah S., Jens J.K., Snella E.M., Kline K.L., Parkes J.D., Ware W.A., Moran L.E., Fales-Williams A.J., Wengert J.A., Whitley R.D., Betts D.M., Boal A.M., Riedesel E.A., Gross W., Ellinwood N.M., Dickson P.I. Replacing the enzyme alpha-l-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci. Transl. Med. 2010, 2:60-89.
28. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22:659-661.
29. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers 2002, U.S. Food and Drug Administration, Rockville, Maryland, USA.
30. Wolf D.A., Hanson L.R., Aronovich E.L., Nan Z., Low W.C., Frey W.H., McIvor R.S. Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration. Mol. Genet. Metab. 2012, 106:131-134.
31. Dickson P., McEntee M., Vogler C., Le S., Levy B., Peinovich M., Hanson S., Passage M., Kakkis E. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol. Genet. Metab. 2007, 91:61-68.
32. Kakkis E., McEntee M., Vogler C., Le S., Levy B., Belichenko P., Mobley W., Dickson P., Hanson S., Passage M. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol. Genet. Metab. 2004, 83:163-174.